CO5611103A2 - Derivados de bencensulfonamida como agentes antisicoticos - Google Patents

Derivados de bencensulfonamida como agentes antisicoticos

Info

Publication number
CO5611103A2
CO5611103A2 CO04079408A CO04079408A CO5611103A2 CO 5611103 A2 CO5611103 A2 CO 5611103A2 CO 04079408 A CO04079408 A CO 04079408A CO 04079408 A CO04079408 A CO 04079408A CO 5611103 A2 CO5611103 A2 CO 5611103A2
Authority
CO
Colombia
Prior art keywords
alkyl
optionally substituted
6alkyl
alkoxy
so2nr7r8
Prior art date
Application number
CO04079408A
Other languages
English (en)
Inventor
Steven Mark Bromidge
Cooper David Gwyn
Forbes Ian Thomson
Christopher Norbert Johnson
Andrew P Lightffot
Stephen Frederick Newby
Andrew H Payne
Sharooq Rahman Shahzad
David R Witty
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0203437A external-priority patent/GB0203437D0/en
Priority claimed from GB0203438A external-priority patent/GB0203438D0/en
Priority claimed from GB0204784A external-priority patent/GB0204784D0/en
Priority claimed from GB0204758A external-priority patent/GB0204758D0/en
Priority claimed from GB0212548A external-priority patent/GB0212548D0/en
Priority claimed from GB0219711A external-priority patent/GB0219711D0/en
Priority claimed from GB0224466A external-priority patent/GB0224466D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CO5611103A2 publication Critical patent/CO5611103A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

1.- Un compuesto de fórmula (I):en donde A y B representan los grupos (CH2)m- y -(CH2)n-, respectivamente;R1 representa hidrógeno o alquilo de C1-6; R2 representa hidrógeno, halógeno, hidroxi, ciano, nitro, hidroxialquilo de C1-6, trifluorometilo, trifluorometoxi, alquilo de C1-6, alcoxi de C1-6, alcoxi de C1-6 alquilo de C1-6, cicloalquilo de C3-7 alcoxi de C1-6, -(CH2)pcicloalquilo de C3-6, -(CH2)pcicloalquiloxi de C3-6, -COalquilo de C1-6, -SO2alquilo de C1-6, -SOalquilo de C1-6, -S-alquilo de C1-6, alquilsulfoniloxi de C1-6, alquilsulfonilo de C1-6 alquilo de C1-6, -C02alquilo de C1-6, -C02NR7R8, -SO2NR7R8, alquilsulfonamido de C1-6, alquilsulfonilamido de C1-6 alquilo de C1-6, -(CH2)pNR7R8, alquilamido de C1-6 alquilo de C1-6, -(CH2)pNR7COR8, arilsulfonilo, arilsulfoniloxi, arilsulfonilalquilo de C1-6, arilsulfonamido, arilcarboxamido, arilsulfonamidoalquilo de C1-6, arilcarboxamidoalquilo de C1-6, aroilo, aroilalquilo de C1-6, arilalcanoilo de C1-6, -SO2NR7R8, arilo sustituido opcionalmente, heteroarilo sustituido opcionalmente o heterocíclilo sustituido opcionalmente, o un grupo CONR7R8 o SO2NR7R8, en donde R7 y R8 juntos pueden estar fusionados para formar un anillo heterocíclico aromático o no aromático de 5-7 miembros interrumpido opcionalmente por un átomo de O o S; R3 representa hidrógeno o alquilo de C1-6; Ar representa fenilo sustituido opcionalmente o un grupo heteroarilo monocíclico sustituido opcionalmente; R4 representa arilo sustituido opcionalmente o heteroarilo sustituido opcionalmente; R7 y R8 cada uno de manera independiente, representa hidrógeno, alquilo de C1-6 o juntos forman un anillo heterocíclico de 5 a 7 miembros; Z representa un enlace, un átomo de oxígeno o alquilo de C1-6; Y representa hidrógeno o alquilo de C1-6; m y n de manera independiente representan un entero seleccionado de 1 y 2; p de manera independiente representa un entero seleccionado de 0, 1, 2 y 3; q representa un entero de 1 a 3; r representa un entero de 1 a 4; o una sal o solvato farmacéuticamente aceptable del mismo.
CO04079408A 2002-02-13 2004-08-13 Derivados de bencensulfonamida como agentes antisicoticos CO5611103A2 (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB0203437A GB0203437D0 (en) 2002-02-13 2002-02-13 Novel compounds
GB0203438A GB0203438D0 (en) 2002-02-13 2002-02-13 Compounds
GB0204784A GB0204784D0 (en) 2002-02-28 2002-02-28 Compounds
GB0204758A GB0204758D0 (en) 2002-02-28 2002-02-28 Novel compounds
GB0212548A GB0212548D0 (en) 2002-05-30 2002-05-30 Novel compounds
GB0219711A GB0219711D0 (en) 2002-08-23 2002-08-23 Novel compounds
GB0224466A GB0224466D0 (en) 2002-10-21 2002-10-21 Compounds

Publications (1)

Publication Number Publication Date
CO5611103A2 true CO5611103A2 (es) 2006-02-28

Family

ID=27739513

Family Applications (1)

Application Number Title Priority Date Filing Date
CO04079408A CO5611103A2 (es) 2002-02-13 2004-08-13 Derivados de bencensulfonamida como agentes antisicoticos

Country Status (14)

Country Link
US (1) US20050222124A1 (es)
EP (1) EP1474399A1 (es)
JP (1) JP2005526724A (es)
KR (1) KR20040081201A (es)
CN (1) CN1630642A (es)
AU (1) AU2003215558A1 (es)
BR (1) BR0307557A (es)
CA (1) CA2475783A1 (es)
CO (1) CO5611103A2 (es)
IS (1) IS7388A (es)
MX (1) MXPA04007920A (es)
NO (1) NO20043794L (es)
PL (1) PL371344A1 (es)
WO (1) WO2003068752A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2260607T3 (es) * 2002-02-13 2006-11-01 Glaxo Group Limited Derivados de 7-arilsulfonamido-2,3,4,5-tetrahidro-1h-benzo-diazepina con afinidad por los receptores 5-ht6 para el tratamiento de trastornos del snc.
US20050085461A1 (en) * 2002-02-13 2005-04-21 Cooper David G. Benzenesulfonamide derivatives
TWI281914B (en) 2002-05-29 2007-06-01 Glaxo Group Ltd Compounds
AU2003273969A1 (en) * 2002-10-07 2004-04-23 Glaxo Group Limited Sulfonamide derivatives as antipsychotic agents
GB0321475D0 (en) * 2003-09-12 2003-10-15 Glaxo Group Ltd Novel compounds
GB0327737D0 (en) * 2003-11-28 2003-12-31 Glaxo Group Ltd Novel compounds
GB0327740D0 (en) * 2003-11-28 2003-12-31 Glaxo Group Ltd Novel compounds
GB0327741D0 (en) * 2003-11-28 2003-12-31 Glaxo Group Ltd Novel compounds
GB0327738D0 (en) * 2003-11-28 2003-12-31 Glaxo Group Ltd Novel compound
ES2375963T3 (es) * 2003-12-18 2012-03-07 Abbott Gmbh & Co. Kg Tetrahidrobenzacepinas y su uso en la modulación del receptor d3 de la dopamina.
US20050137186A1 (en) * 2003-12-18 2005-06-23 Abbott Gmbh & Co. Kg. Tetrahydrobenzazepines and their use
WO2005123723A1 (en) * 2004-06-18 2005-12-29 Glaxo Group Limited 3-cycloalkylbenzazepines as histamine h3 antagonists
EP1812416B1 (en) * 2004-10-14 2013-08-21 Abbott GmbH & Co. KG Arylsulfonylmethyl or arylsulfonamide substituted aromatic compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor
FR2878524B1 (fr) * 2004-12-01 2007-01-19 Bioprojet Soc Civ Ile Nouveaux derives d'arylpiperazine
WO2006062481A1 (en) * 2004-12-09 2006-06-15 Biovitrum Ab New benzofuran derivatives and their use in the treatment of obesity, type ii diabetes and cns disorders .
EP1837332A1 (en) * 2006-03-23 2007-09-26 Laboratorios Del Dr. Esteve, S.A. Substituted tetrahydroisoquinoline compounds, their preparation and use in medicaments
EP2314577A1 (en) * 2009-10-16 2011-04-27 Almirall, S.A. Process for manufacturing 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid
CN103145619A (zh) * 2012-06-15 2013-06-12 史慎德 7-氯-6-苯磺酰氨基-2,3,4,5-四氢-1H-苯并[d]氮杂*的制备
CA3017048C (en) * 2016-03-22 2023-11-07 Helsinn Healthcare Sa Benzenesulfonyl-asymmetric ureas and medical uses thereof
PE20230847A1 (es) * 2020-09-23 2023-05-23 St Jude Childrens Res Hospital Inc Analogos de n-(2-(2,6-dioxopiperidin-3-il)-1,3-dioxoisoindolin-5-il)arilsufonamida sustituidos como modulares de la proteina cereblon

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DZ2376A1 (fr) * 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
BR9810991A (pt) * 1997-07-11 2000-08-08 Smithkline Beecham Plc Novos compostos
GB9801392D0 (en) * 1998-01-22 1998-03-18 Smithkline Beecham Plc Novel compounds
GB9803411D0 (en) * 1998-02-18 1998-04-15 Smithkline Beecham Plc Novel compounds
GB9926302D0 (en) * 1999-11-05 2000-01-12 Smithkline Beecham Plc Novel compounds
ES2260607T3 (es) * 2002-02-13 2006-11-01 Glaxo Group Limited Derivados de 7-arilsulfonamido-2,3,4,5-tetrahidro-1h-benzo-diazepina con afinidad por los receptores 5-ht6 para el tratamiento de trastornos del snc.
US20050085461A1 (en) * 2002-02-13 2005-04-21 Cooper David G. Benzenesulfonamide derivatives

Also Published As

Publication number Publication date
KR20040081201A (ko) 2004-09-20
CA2475783A1 (en) 2003-08-21
BR0307557A (pt) 2005-01-04
IS7388A (is) 2004-08-06
MXPA04007920A (es) 2004-11-26
WO2003068752A1 (en) 2003-08-21
US20050222124A1 (en) 2005-10-06
EP1474399A1 (en) 2004-11-10
CN1630642A (zh) 2005-06-22
AU2003215558A1 (en) 2003-09-04
JP2005526724A (ja) 2005-09-08
NO20043794L (no) 2004-09-10
PL371344A1 (en) 2005-06-13

Similar Documents

Publication Publication Date Title
CO5611103A2 (es) Derivados de bencensulfonamida como agentes antisicoticos
AR039127A1 (es) Compuesto de quinolina, procedimiento para su preparacion, composicion farmaceutica que lo comprende y uso del mismo para la fabricacion de un medicamento
AR107966A2 (es) Derivados de pirimidina y piridina inhibidores de la proteína quinasa
ECSP066967A (es) Derivados de tetrahidroquinolina y un procedimiento para preparar los mismos
UY29393A1 (es) Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones.
HRP20080227T3 (en) Pyrrolidine derivatives as histamine receptors ligands
ATE293101T1 (de) Piperidine zur verwendung als orexin rezeptor antagonisten
AR025975A1 (es) Compuestos quimicos.
AR029614A1 (es) Derivados de 4-fenil-piridina, su uso, un proceso para prepararlos, y medicamentos que los contienen
AR060593A1 (es) 5-amido-2-carboxiamida-indoles
AR049110A1 (es) Compuestos terapeuticos: piridina como andamiaje estructural
AR050436A1 (es) Inhibidores de azaindol de mtp y apob
AR058769A1 (es) Inhibidores de peptidil-deformilasa(pdf),utiles para el tratamiento de la tuberculosis y composiciones farmaceuticas que los contienen.
AR052943A1 (es) Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida
AR061486A1 (es) Derivados de 2-pirazinacarboxamida
AR038341A1 (es) Compuestos que son agonistas de receptores alfa-1 preferentemente agonistas de receptores alfa-1a/l
HRP20090264T1 (en) Phenyl-piperazin methanone derivatives
AR059094A1 (es) Derivados de ciclohexil - sulfonamida
NO952208D0 (no) Amin-derivater
AR040626A1 (es) Derivados de quinolina utiles como ligandos del receptor del neuropeptido y (npy)
AR047958A1 (es) Derivados de 1-bencil-5-piperazin-1-il-3,4 dihidro-1h-quinazolin-2-ona y sus derivados 1h-benzo(1,2,6)tiadiazina-2,2-dioxidos y 1,4-dihidro-benzo(d)(1,3)oxazinas-2-ona,como moduladores del receptor 5-ht,para el tratamiento de enfermedades del sistema nervioso central.
DE60110896D1 (de) Carboxamide und ihre verwendung als inhibitoren des mikrosomalen triglycerid-transfer-proteins und der apolipoprotein b (apo b) sekretion
AR066604A1 (es) Derivados de arilamida pirimidona, medicamentos que los contienen y usos terapeuticos para prevenir y/o tratar enfermedades neurodegenerativas fundamentalmente.
DK1717229T3 (da) Ny cyklisk forbindelse med 4-pyridylalkylthiogruppe med deri indført (u)substitueret amino
SE0101579D0 (sv) New compounds

Legal Events

Date Code Title Description
FA Application withdrawn